Highest-materiality recent filing
Genprex reports positive predictive biomarker data for Reqorsa in NSCLC at ASCO 2026
In NSCLC patients, Trop-2 H-score >100 and PTEN H-score <100 correlated with prolonged PFS (p=0.05, p=0.03).
Genprex diabetes gene therapy GPX-002 reverses hyperglycemia in T2D mouse model
Preclinical data presented at ASGCT 2026 showed GPX-002 reversed hyperglycemia in Type 2 diabetic mice within 4 weeks.
Genprex granted Israel patent for Reqorsa gene therapy with PD-1 antibodies
Israel Patent Office granted patent covering Reqorsa (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment.
Genprex' GPX-002 reverses hyperglycemia in T2D mouse models; data at ASGCT 2026
GPX-002 (Pdx1/MafA gene therapy) reversed hyperglycemia in HFD-induced T2D mouse models within 4 weeks post-treatment.
Genprex inks new MD Anderson SRA for Reqorsa biomarkers; trial updates show partial responses
New Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN as biomarkers for Reqorsa in NSCLC and SCLC.
Genprex announces positive preclinical data for Reqorsa at AACR 2026
TROP2 and PTEN identified as potential biomarkers of primary resistance to TUSC2 gene therapy; 50% of NSCLC cell lines resistant.
Genprex wins Japanese and European patent grants for REQORSA combos; Acclaim-3 update
Japanese Patent Office issued favorable Appeal Decision to grant patent for REQORSA + PD-L1 antibodies.
Genprex gets Australian patent acceptance for Reqorsa+PD-L1; adds trial site
IP Australia issued Notice of Acceptance on Feb 5, 2026 for patent covering Reqorsa + PD-L1 antibodies in cancer.
Genprex regains Nasdaq minimum $2.5M equity compliance; one-year monitoring imposed
Received Nasdaq Compliance Notice on Jan 7, 2026, reaffirming compliance with Listing Rule 5550(b)(1).
Initiated preclinical research in Type 2 diabetic animal models; in vivo proof-of-concept showed normalized glucose levels.
First T2D NHP received intraductal AAV infusion of GPX-002 (Pdx1+MafA) and showed normal glucose tolerance test at 7 months.
Genprex believes it now meets Nasdaq minimum equity requirement; Panel yet to rule
Company raised proceeds from registered direct offerings (Oct 24 and 29, 2025), ATM with H.C. Wainwright, and equity line with Lincoln Park to boost equity.
Genprex (GNPX) regains Nasdaq bid price compliance, gets equity exception to Dec 31
Nasdaq Panel confirmed Genprex regained compliance with Minimum Bid Price requirement ($1.00).
Genprex files to sell up to $75M in common stock via ATM with H.C. Wainwright
Filed Nov 21, 2025 prospectus supplement for up to $75M of common stock under existing ATM agreement.
Genprex adds Gabrail Cancer Center as new site for Acclaim-1 and Acclaim-3 Reqorsa trials
Gabrail Cancer Center (Canton, OH) is new clinical trial site for Acclaim-1 (NSCLC) and Acclaim-3 (ES-SCLC) studying Reqorsa gene therapy.
Genprex granted US patent for REQORSA plus PD-L1 antibody combo through 2037
USPTO patent covers REQORSA gene therapy combined with PD-L1 antibodies like Tecentriq, securing exclusivity to 2037.
Genprex announces European Patent Office intent to grant patent for Reqorsa with PD-1 antibodies
European Patent Office communicated intent to grant patent for Reqorsa gene therapy combined with PD-1 antibodies for cancer.
Genprex raises ~$3.4M in registered direct offering plus up to $6.6M from warrant exercise
Offering: 377,780 shares at $9.00/share; gross proceeds ~$3.4M before fees.
Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC
REQORSA overexpressed TUSC2 tumor suppressor gene in ALK-EML4+ NSCLC cell lines and patient derived organoids.
Issued 243,622 shares at $11.21/sh for ~$2.7M gross proceeds; net ~$2.3M after fees.
Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC conference
Reqorsa plus alectinib shrank tumors by 79% vs 60% with alectinib alone in mouse xenograft model.
Genprex effects 1:50 reverse stock split; shares outstanding reduced to ~1M
Reverse stock split of common stock at 1:50 ratio effective October 21, 2025.
Genprex granted Nasdaq exception through Oct 31, 2025; 1-for-50 reverse stock split effective Oct 21
Nasdaq Panel exception to demonstrate compliance with $1.00 bid price and $2.5M stockholders' equity until Oct 31, 2025; Panel may extend to Feb 9, 2026.
Genprex faces Nasdaq delisting for both equity and bid price non-compliance; hearing requested
Stockholders' equity of $1.39M as of June 30, 2025, below Nasdaq's $2.5M minimum requirement.
USPTO issued notice of allowance for patent covering REQORSA + PD-L1 antibodies (e.g., Tecentriq); EPO issued allowance for REQORSA + PD-1 antibodies; both expire 2037.
Genprex stockholders approve reverse split (1:10-1:50), 6.5M new shares for equity plan
Approved Amended & Restated 2018 Equity Plan, adding 6,500,000 shares and extending term to June 30, 2035.
Genprex issues 2025 corporate update; two lung cancer trials ongoing
Patient treatment continues in two lung cancer clinical trials.
Genprex reports positive preclinical data for diabetes gene therapy GPX-002 at ADA
Alpha cells in Type 1 diabetes mouse models transdifferentiated to insulin-secreting beta-like cells after GPX-002 infusion.
Genprex reports positive preclinical data for GPX-002 using lipid nanoparticle delivery at ADA 2025
Nine LNPs tested; two were highly efficient in transfecting α- and β-cells in isolated mouse islets.
Genprex secures $12.5M equity line with Lincoln Park; provides clinical trial updates
Entered purchase agreement for up to $12.5M in common stock; issued 1,186,859 commitment shares to Lincoln Park.
Genprex regains Nasdaq stockholders' equity compliance; bid price issue unresolved
Received Nasdaq confirmation on June 6, 2025 that it regained compliance with stockholders' equity requirement of $2.5M.
New SRA with Pitt for preclinical studies of GPX-002 in T1D and T2D animal models.
Genprex licenses exclusive patent rights to Reqorsa for glioblastoma from UTHealth Houston
Exclusive patent license with UTHealth Houston grants Genprex commercial rights to Reqorsa for GBM.
Genprex licenses NYU patent for Reqorsa gene therapy in mesothelioma; TUSC2 down in 84%
Exclusive patent license with NYU Langone Health for Reqorsa (quaratusugene ozeplasmid) to treat mesothelioma.
Entered amended and restated exclusive license with Univ of Pittsburgh for T1D and T2D gene therapy using Pdx1 and MafA genes.
Genprex receives Nasdaq deficiency notices for bid price and equity requirements
Nasdaq notified Genprex on Feb 7, 2025 that its stock closed below $1.00 for 30 consecutive business days, non-compliant with Rule 5550(a)(2).
Phase 2 expansion will enroll ~50 patients at 10-15 U.S. sites; primary endpoint is 18-week progression-free survival rate.
Genprex provides clinical trial updates for Acclaim-1, Acclaim-3, and diabetes gene therapy program
Acclaim-1 Phase 2a expansion enrolling; interim analysis after 19 patients expected H2 2025.
Genprex completes Phase 1 dose escalation of Reqorsa + Tecentriq in ES-SCLC; Phase 2 opens
No dose-limiting toxicities observed; RP2D set at 0.12 mg/kg (highest dose tested).
Genprex enters exclusive license with Univ of Michigan for Reqorsa in ALK+ lung cancer
License grants Genprex worldwide exclusive rights to University of Michigan patents for Reqorsa gene therapy combined with ALK-inhibitors for ALK-EML4 positive NSCLC.
Genprex receives Nasdaq delisting notice for failing minimum stockholders' equity requirement
Stockholders' equity of $1,664,971 as of Sept 30, 2024, below the Nasdaq minimum of $2.5 million.
Genprex regains Nasdaq minimum bid price compliance; delisting risk resolved
Received Nasdaq letter on Nov 4, 2024 confirming compliance with Listing Rule 5550(a)(2).
Genprex partners with U Michigan to study REQORSA plus ALK-inhibitors in ALK+ lung cancer
Entered Sponsored Research Agreement with Univ. of Michigan Rogel Cancer Center for TUSC2/REQORSA combo with ALK-inhibitors.
Completed 0.09 mg/kg dose group of Reqorsa + Tecentriq in ES-SCLC Phase 1; no dose-limiting toxicities reported.
Genprex receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period
Nasdaq letter dated Sept 26, 2024; stock fails minimum $1.00 bid price for 30 consecutive business days.
Genprex to spin out diabetes gene therapy program into new subsidiary GPX-002
Intends to transfer diabetes clinical development and gene therapy assets to wholly-owned NewCo.
Genprex granted Singapore patent for Reqorsa with anti-PD-1 antibodies through 2037
Singapore Patent Office grants patent covering Reqorsa (quaratusugene ozeplasmid) in combo with anti-PD-1 antibodies until 2037.
Genprex begins treating patients in two new lung cancer trials, continues third
Opened enrollment and began treating patients in two new lung cancer clinical trials in 2024.
Genprex CEO Confer Gets Salary Hike, Title Upgrade; Former EVP Vaczy Receives $350K Severance
Ryan Confer confirmed as President, CEO and CFO; base salary increased to $480,000 per year; severance reference period extended from 12 to 18 months.
Genprex CEO Rodney Varner dies; CFO Ryan Confer appointed CEO and Board member
CEO/President/Chairman Rodney Varner passed away unexpectedly on May 7, 2024 due to illness complications.
Mr. Confer’s title change to President, Chief Executive Officer and Chief Financial Officer was confirmed
Catherine Vaczy, the Company’s then Executive Vice President, General Counsel and Chief Strategy Officer, notified the Company of her intention to resign.
the Board appointed Ryan Confer, Chief Financial Officer of Genprex since 2016, to serve as President and Chief Executive Officer of Genprex (in addition to his position as Chief Financial Officer of Genprex), effective immediately
On May 8, 2024, Mr. Confer was also appointed to the Board as a Class III director to fill the vacancy caused by Mr. Varner’s passing
Rodney Varner, the Company’s President and Chief Executive Officer and Chairman of the Company’s Board of Directors (the “Board”), passed away unexpectedly on May 7, 2024 due to complications from an ongoing illness.
the Board has determined that Mr. Confer can and shall act alone in covering when Mr. Varner is unavailable.
Catherine Vaczy, the Executive Vice President, General Counsel and Chief Strategy Officer of Genprex, Inc. (“Genprex” or the “Company”) notified the Company of her intention to resign. On February 4, 2024, Ms. Vaczy’s employment with the Company was terminated.
On January 30, 2024, Catherine Vaczy provided Genprex, Inc. (“Genprex” or the “Company”) with a notice of her intention to resign pursuant to Section 7.4 of her Executive Employment Agreement
Max materiality 0.85 · Median 0.60 · Most common event other_material